Hindering of proteinopathy-induced neurodegeneration as a new mechanism of action for neuroprotectors and cognition enhancing compounds.
Bachurin
S O
SO
Institute of Physiologically Active Compounds of the Russian Academy of Sciences, Chernogolovka, Russia. bachurin@ipac.ac.ru
Ustyugov
A A
AA
Peters
O
O
Shelkovnikova
T A
TA
Buchman
V L
VL
Ninkina
N N
NN
D000682:Amyloid / Q000737:chemistry / Q000378:metabolism; D000818:Animals; D003071:Cognition / Q000187:drug effects*; D055808:Drug Discovery; D005911:Gliosis / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D055503:Protein Multimerization / Q000187:drug effects; D055550:Protein Stability; D020836:Protein Structure, Quaternary; D011506:Proteins / Q000737:chemistry / Q000378:metabolism*; D051843:Synucleins / Q000737:chemistry / Q000378:metabolism
D000682:Amyloid; D007211:Indoles; D018696:Neuroprotective Agents; D011506:Proteins; D051843:Synucleins; C010119:latrepirdine